These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20477604)

  • 1. Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.
    Stein ML; Rothenberg ME
    Expert Rev Clin Immunol; 2005 Nov; 1(4):633-44. PubMed ID: 20477604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL-5 and hypereosinophilic syndromes.
    Sutton SA; Assa'ad AH; Rothenberg ME
    Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW; Ring J; Huss-Marp J; Kahn JE
    J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypereosinophilic syndrome: diagnosis and treatment.
    Peros-Golubicić T; Smojver-Jezek S
    Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
    Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
    J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypereosinophilic syndrome: an update.
    Wilkins HJ; Crane MM; Copeland K; Williams WV
    Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypereosinophilic syndrome and proliferative diseases.
    Ionescu MA; Wang L; Janin A
    Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].
    Chrobák L; Voglová J
    Vnitr Lek; 2005 Dec; 51(12):1385-93. PubMed ID: 16430106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date].
    Kahn JE; Grandpeix-Guyodo C; Ackermann F; Charles P; Legrand F; Blétry O
    Rev Med Interne; 2010 Apr; 31(4):268-76. PubMed ID: 20303627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral mucosa lesions in hypereosinophilic syndrome--an update.
    Ionescu MA; Murata H; Janin A
    Oral Dis; 2008 Mar; 14(2):115-22. PubMed ID: 18194138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
    Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Practical approach to hypereosinophilia].
    Roufosse F; Cogan E
    Rev Med Brux; 2008 Sep; 29(4):400-8. PubMed ID: 18949995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
    Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
    Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.